Company Overview
| Stock Name | Chaoju Eye Care |
|---|---|
| Stock Code | 02219 |
| Company Full Name | To be extracted |
| Industry | Healthcare |
| Principal Activities | 我們是中國華北地區領先、全國知名的眼科醫療服務集團，主要提供消費眼科服務（屈光矯正、近視防控及視光產品）及基礎眼科服務（白內障、青光眼、眼底疾病等常見眼科疾病治療）。 |
| Listing Date | 2021-07-07 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 北京 豐台區 西三環南路14號院 首科大廈A座 東區24層 |
| Business Address (Hong Kong) | 香港 灣仔 皇后大道東248號 大新金融中心 40樓 |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | www.chaojueye.com |
| Share Registrar | 香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited) |
| Registrar Contact | (852)2862 8628 |
| A-Share/US Dual Listing | No |
Offering Information
| Offering Mechanism | Mechanism A |
|---|---|
| Offer Price | HK$ 10.60 / shares |
| Offer Price Range | Final offer price only, no range |
| Lot Size | 500 shares |
| Entry Threshold | HK$ 5,300 |
| Par Value | RMB 0.00025 / shares |
| Offer Period | 2021-06-24 to 2021-06-29 |
| Global Offering Shares | 170,930,000 shares |
| HK Public Offer Shares (Initial) | 17,093,000 shares (10.0%) |
| Public Offer Lots (Initial) | 34,186lots (Pool A17,093lots，Pool B17,093lots) |
| International Placing Shares (Initial) | 153,837,000 shares (90.0%) |
| Offer Ratio | ~10.0% |
| Total Shares Post-IPO | 687,500,000 shares |
| Greenshoe (Over-allotment Option) | Yes |
| Stabilizing Manager (Greenshoe) | To be extracted |
| Cornerstone Share | 43.7% |
| Clawback Tiers | To be extracted |
| Reallocation Option | Yes |
| Total Global Offering Size | HK$ 1,811,858,000 |
Subscription Tiers
Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.
Pool A
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 1 lots | 500 | HK$ 5,300 |
| 2 lots | 1,000 | HK$ 10,600 |
| 3 lots | 1,500 | HK$ 15,900 |
| 4 lots | 2,000 | HK$ 21,200 |
| 5 lots | 2,500 | HK$ 26,500 |
| 6 lots | 3,000 | HK$ 31,800 |
| 7 lots | 3,500 | HK$ 37,100 |
| 8 lots | 4,000 | HK$ 42,400 |
| 9 lots | 4,500 | HK$ 47,700 |
| 10 lots | 5,000 | HK$ 53,000 |
| 12 lots | 6,000 | HK$ 63,600 |
| 14 lots | 7,000 | HK$ 74,200 |
| 16 lots | 8,000 | HK$ 84,800 |
| 18 lots | 9,000 | HK$ 95,400 |
| 20 lots | 10,000 | HK$ 106,000 |
| 30 lots | 15,000 | HK$ 159,000 |
| 40 lots | 20,000 | HK$ 212,000 |
| 50 lots | 25,000 | HK$ 265,000 |
| 60 lots | 30,000 | HK$ 318,000 |
| 70 lots | 35,000 | HK$ 371,000 |
| 80 lots | 40,000 | HK$ 424,000 |
| 90 lots | 45,000 | HK$ 477,000 |
| 100 lots | 50,000 | HK$ 530,000 |
| 120 lots | 60,000 | HK$ 636,000 |
| 140 lots | 70,000 | HK$ 742,000 |
| 160 lots | 80,000 | HK$ 848,000 |
| 180 lots | 90,000 | HK$ 954,000 |
| 200 lots | 100,000 | HK$ 1,060,000 |
| 400 lots | 200,000 | HK$ 2,120,000 |
| 600 lots | 300,000 | HK$ 3,180,000 |
| 800 lots | 400,000 | HK$ 4,240,000 |
Pool B
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 1,000 lots | 500,000 | HK$ 5,300,000 |
| 1,200 lots | 600,000 | HK$ 6,360,000 |
| 1,400 lots | 700,000 | HK$ 7,420,000 |
| 1,600 lots | 800,000 | HK$ 8,480,000 |
| 1,800 lots | 900,000 | HK$ 9,540,000 |
| 2,000 lots | 1,000,000 | HK$ 10,600,000 |
| 4,000 lots | 2,000,000 | HK$ 21,200,000 |
| 6,000 lots | 3,000,000 | HK$ 31,800,000 |
| 8,000 lots | 4,000,000 | HK$ 42,400,000 |
| 10,000 lots | 5,000,000 | HK$ 53,000,000 |
| 12,000 lots | 6,000,000 | HK$ 63,600,000 |
| 14,000 lots | 7,000,000 | HK$ 74,200,000 |
| 16,000 lots | 8,000,000 | HK$ 84,800,000 |
| 17,093 lots | 8,546,500 | HK$ 90,592,900 |
Stock Connect Inclusion Analysis
| 26Q4 Regular Review | |
| Inclusion Pathway | Regular Path |
|---|---|
| HK Market Cap | HK$ 1.8B |
| Est. Threshold | HK$ 9.44B |
| Analysis Result | HK market cap below threshold, need +425% |
Valuation & Financials
| Market Cap (at Offer Price) | HK$ 7,287,500,000 |
|---|---|
| Pre-IPO Valuation (Last Round) | Not disclosed |
| P/E Ratio | Not disclosed |
| Profit/Loss Status | 盈利約人民幣120.5百萬元 |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
Financial Data
Unit:
'000
RMB
Income Statement
| Item | 2018 | 2019 | 2020 |
|---|---|---|---|
| Revenue | 632,659 | 714,671 | 794,282 |
| Cost of sales | -387,707 | -436,630 | -444,762 |
| Gross profit | 244,952 | 278,041 | 349,520 |
| Other income and gains, net | 7,970 | 12,894 | 7,351 |
| Selling and distribution expenses | -35,863 | -34,531 | -32,892 |
| Administrative expenses | -129,341 | -118,132 | -133,527 |
| Net finance costs | -24,268 |
Income Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
| First Day Close | HK$ 14.1 |
|---|---|
| First Day Open | HK$ 10.6 |
| First Day Change | 33.02% |
| First Day Volume | 165726000.0 |
| First Day Turnover | 2121820000.0 |
| Use of Proceeds | 1、約35.8%（或485.5百萬港元）將用于建立新醫院以及搬遷、升級及裝修現有醫院；
2、約44.8%（或608.4百萬港元）將在出現合適機遇時，用于在人口龐大且對眼科醫療服務需求相對較高的新市場中收購醫院；
3、約9.4%（或127.5百萬港元）將用于升級我們的信息技術系統；
4、約10.0%（或135.7百萬港元）將用于營運資金及其他一般企業用途。 |
Underwriting Syndicate
Overall Coordinators (2)
Joint Lead Managers (2)
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | Gigantic Wealth Holdings Limited | 155,205,200 HKD | — | 8.57% | — | 6 months | 2022-01-07 |
| 2 | The Valliance Fund | 155,205,200 HKD | — | 8.57% | — | 6 months | 2022-01-07 |
| 3 | 富国基金管理有限公司 | 349,217,000 HKD | — | 19.27% | — | 6 months | 2022-01-07 |
| 4 | 通柏资本(香港)有限公司 | 131,922,300 HKD | — | 7.28% | — | 6 months | 2022-01-07 |
Directors & Management
| Position | Chinese name | English Name |
|---|---|---|
| Chairman | 張波洲 | — |
| Company Secretary | 王維超、鄭程傑 | — |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 張波洲先生、張小利女士、張俊峰先生、張豐生先生、張玉梅女士及其控制的Jutong Medical Management、Sihai Medical Management、Guangming Medical Management、Xiwang Medical Management、Sitong Medical Management及廈門聚鷺達洲股權投資，緊隨全球發售完成後合共持有約41.61%股份。 |
|---|
